( whole genomeamplified DNA. We used only...)Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies

The CMA data (Fig. 1) shows that CGH microarray analysis of the Down syndrome patient is consistent with a genomic gain, as detected by 14 out of 15 determined target clones in the array for both unamplified and amplified DNA. It reflects the presence of a third chromosome 21 (Table 1). Furthermore, the array for Edwards syndrome (Fig. 2) showed a genomic gain in 30 of 33 possible test clones for the unamplified genomic DNA sample and a gain of 27 target clones from 33 possible test clones in the whole genomeamplified DNA sample in the region tested for chromosome (Table 2). This represents a strong indication of trisomy 18.

The data presented here demonstrate that the GenomePlex WGA kit amplifies limited amounts of DNA without bias, producing material that is suitable for use with the CMA assay, allowing for the identification of genome-wide copy number and chromosomal abnormalities.

Additional information is available online (http://www.sigma.com/wga).

ACKNOWLEDGMENTS
We thank S.W. Cheung, X. Lu, S.D. Bland and A. Beaudet from the microarray facilities in the Department of Molecular and Human Genetics at Baylor College of Medicine (Houston, USA). We acknowledge E. Mueller, K. Kayser, A. Favello and R. Valdes-Camin from Sigma-Aldrich Co. for helpful discussions and support.

back to top
'"/>

Source: